Tamarly Lists · Tuesday · Trial phase steps

12 medicines that moved to the next trial phase this week

30 medicines from company sponsors entered a higher trial phase in trials registered on ClinicalTrials.gov from 27 October 2026 to 2 November 2026; the 12 below lead by phase and trial size.

As of . Research from public records, not investment advice.

  1. Multivalent Group B streptococcus vaccine (Pfizer): First Phase 3 trial, after Phase 2 trials. Healthy volunteers, 6,000 participants planned.
    Source: ClinicalTrials.gov, registered 28 October 2026
  2. Olatorepatide (Regeneron Pharmaceuticals): First Phase 3 trial, after Phase 2 trials. Overweight or Obesity Without Diabetes, 3,000 participants planned.
    Source: ClinicalTrials.gov, registered 27 October 2026
  3. Tulisokibart (Merck Sharp & Dohme LLC): First Phase 3 trial, after Phase 2 trials. Crohn Disease, 1,380 participants planned.
    Source: ClinicalTrials.gov, registered 31 October 2026
  4. lorundrostat (Mineralys Therapeutics Inc.): First Phase 3 trial, after Phase 2 trials. Hypertension, 1,076 participants planned.
    Source: ClinicalTrials.gov, registered 28 October 2026
  5. Envudeucitinib (Alumis Inc): First Phase 3 trial, after Phase 2 trials. Plaque Psoriasis, 912 participants planned.
    Source: ClinicalTrials.gov, registered 29 October 2026
  6. VE303 (Vedanta Biosciences, Inc.): First Phase 3 trial, after Phase 2 trials. Clostridium Difficile, 852 participants planned.
    Source: ClinicalTrials.gov, registered 31 October 2026
  7. Iza-bren (Bristol-Myers Squibb): First Phase 3 trial, after Phase 2/3 trials. Non-Small Cell Lung Cancer, 850 participants planned.
    Source: ClinicalTrials.gov, registered 27 October 2026
  8. PEGCETACOPLAN (APL-2) (Apellis Pharmaceuticals, Inc.): First Phase 3 trial, after Phase 2 trials. Geographic Atrophy Secondary to Age-related Macular Degeneration, 792 participants planned.
    Source: ClinicalTrials.gov, registered 29 October 2026
  9. Ammoxetine (CSPC ZhongQi Pharmaceutical Technology Co., Ltd.): First Phase 3 trial, after Phase 2 trials. Major Depressive Disorder (MDD), 786 participants planned.
    Source: ClinicalTrials.gov, registered 31 October 2026
  10. INCA33890 (Incyte Corporation): First Phase 3 trial, after Phase 2 trials. CRC (Colorectal Cancer), 700 participants planned.
    Source: ClinicalTrials.gov, registered 31 October 2026
  11. FH-006 (Jiangsu HengRui Medicine Co., Ltd.): First Phase 3 trial, after Phase 1/2 trials. Locally Advanced, Recurrent or Metastatic ESCC Patients Who Have Failed Prior PD-1/PD-L1 Inhibitors Combined With Platinum-based Chemotherapy, 480 participants planned.
    Source: ClinicalTrials.gov, registered 28 October 2026
  12. JNJ-101556143 (Janssen Research & Development, LLC): First Phase 3 trial, after Phase 2 trials. Prostatic Neoplasms, 400 participants planned.
    Source: ClinicalTrials.gov, registered 31 October 2026

How this list is made

A medicine counts when a company sponsor registers a trial of it at a higher phase (Phase 2, 2/3 or 3) than any of its earlier trials of the same drug. The lead drug of each trial is used; placebo and standard-of-care arms are left out. A new trial is a registration, not a result.

Sources: ClinicalTrials.gov.

See the latest edition